Kronos BioÂ Inc (KRON) Peer Comparison

$0.88

$0.00 (0.00%)

As on 16-Jul-2025 09:30EDT

Market cap

$54 Mln

Revenue (TTM)

$9 Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Edit

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Market cap ($ Mln)	54	92	8,372
Revenue ($ Mln)	9	4	562
Net Profit ($ Mln)	-64.49	-58.21	-155.73
Net Margin (%)	-701.53	-1,514.57	-27.70
RoE (%)	-67.54	-584.12	-47.53
Price to Earnings	--	--	--
Price-To-Book	0.67	7.92	24.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Operating Revenue	9.19	3.84	562.12
Cost of Revenue	0.83	1.44	23.39
Gross Profit	9.85	0.74	488.66
Operating Expenses	79.53	60.81	713.04
Operating Profit (EBIT)	-70.34	-58.57	-174.31
Other Income	0.00	0.00	0.00
Profit before Tax	-64.49	-58.21	-153.89
Provision for Tax	0.00	0.00	1.84
Profit after Tax (Net Income)	-64.49	-58.21	-155.73
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Shareholder's Funds	79.81	10.22	342.13
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	20.45	40.46	602.89
Current Liabilities	7.88	9.68	250.58
Total Liabilities	124.36	35.08	1,179.81

Assets ($ Mln)

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Non-Current Assets	6.27	24.10	493.54
Current Assets	101.87	36.26	702.07
Total Assets	124.36	35.08	1,179.81
Total Debt*	24.09	3.48	122.75
Net Current Assets	93.99	26.58	451.49

Cashflow ($ Mln)

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Cash From Operating Activities	-65.44	-20.71	-192.59
Cash Flow from Investing Activities	85.44	--	-47.50
Cash from Financing Activities	0.25	20.43	273.11
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
ROCE (%)	-57.42	-611.12	-10.09
ROE (%)	-67.54	-584.12	-47.53
ROA (%)	-40.55	-77.95	-11.57
EBIT Margin (%)	-550.46	-1,349.41	-19.26
Net Margin (%)	-701.53	-1,514.57	-27.70
Cash Profit Margin (%)	0.00	0.00	0.00

Growth Ratios

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Revenue Growth (%)	21.15	178.08	99.19
EBIT Growth (%)	53.53	-157.26	74.53
Net Profit Growth (%)	44.60	-45.72	45.98
EPS Growth (%)	46.44	--	48.84
Book Value Growth (%)	-42.96	--	10.47

Valuation Ratios

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Price / Earnings	-0.67	--	-82.06
Price / Book Value	0.65	--	18.43
Dividend Yield (%)	--	--	--
EV/EBITDA	0.49	0.08	260.78
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Debt to Equity	0.00	0.00	1.01
Short term debt to equity ratio	0.05	0.14	0.17
Current Ratio	12.93	3.75	2.80
Quick Ratio	12.93	3.70	2.75
Interest Coverage	-13.30	-592.93	-1.49

Operating Efficiency Ratios

	Kronos BioÂ Inc (KRON)	OncoCyte Corp (OCX)	Blueprint Medicines Corp (BPMC)
Debtors to sales (%)	0.00	92.12	14.20
Asset Turnover	0.06	0.05	0.42
Receivable days	--	203.60	43.35
Inventory Days	--	65.62	315.51
Payable days	140.96	517.30	104.16
Cash Conversion Cycle	--	-248.08	254.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly